Avanir Pharmaceuticals

BioDelivery Sciences names Adrian Hepner vice president

Tuesday, July 30, 2013

Pharmaceutical company BioDelivery Sciences International (BDSI), headquartered in Raleigh, N.C., has hired Adrian Hepner, M.D., Ph.D., as vice president of clinical research and regulatory affairs. Hepner joins BDSI with over 20 years of experience in U.S. and international clinical research and drug development, including development and implementation of the clinical and regulatory strategy for a number of products from early stage development through NDA and E.U. regulatory filings.

[Read More]

Avanir, OptiNose in licensing deal

Wednesday, July 3, 2013

Avanir Pharmaceuticals and OptiNose have entered into an exclusive North American license agreement for the development and commercialization of OptiNose’s novel Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine. If approved, this product would be the first dry-powder nasal delivery form of sumatriptan.

[Read More]